<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?covid-19-tdm?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Mol Divers</journal-id>
    <journal-id journal-id-type="iso-abbrev">Mol Divers</journal-id>
    <journal-title-group>
      <journal-title>Molecular Diversity</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1381-1991</issn>
    <issn pub-type="epub">1573-501X</issn>
    <publisher>
      <publisher-name>Springer International Publishing</publisher-name>
      <publisher-loc>Cham</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8343361</article-id>
    <article-id pub-id-type="pmid">34357513</article-id>
    <article-id pub-id-type="publisher-id">10291</article-id>
    <article-id pub-id-type="doi">10.1007/s11030-021-10291-7</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Anti-Ebola: an initiative to predict Ebola virus inhibitors through machine learning</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Rajput</surname>
          <given-names>Akanksha</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3769-052X</contrib-id>
        <name>
          <surname>Kumar</surname>
          <given-names>Manoj</given-names>
        </name>
        <address>
          <email>manojk@imtech.res.in</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.418099.d</institution-id><institution>Virology Unit and Bioinformatics Centre, Institute of Microbial Technology, </institution><institution>Council of Scientific and Industrial Research (CSIR), </institution></institution-wrap>Sector 39A, Chandigarh, 160036 India </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.469887.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 7744 2771</institution-id><institution>Academy of Scientific and Innovative Research (AcSIR), </institution></institution-wrap>Ghaziabad, 201002 India </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>6</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <year>2022</year>
    </pub-date>
    <volume>26</volume>
    <issue>3</issue>
    <fpage>1635</fpage>
    <lpage>1644</lpage>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>3</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>28</day>
        <month>7</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</copyright-statement>
      <license>
        <license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Ebola virus is a deadly pathogen responsible for a frequent series of outbreaks since 1976. Despite various efforts from researchers worldwide, its mortality and fatality are quite high. For antiviral drug discovery, the computational efforts are considered highly useful. Therefore, we have developed an 'anti-Ebola' web server, through quantitative structure–activity relationship information of available molecules with experimental anti-Ebola activities. Three hundred and five unique anti-Ebola compounds with their respective IC<sub>50</sub> values were extracted from the ‘DrugRepV’ database. Later, the compounds were used to extract the molecular descriptors, which were subjected to regression-based model development. The robust machine learning techniques, namely support vector machine, random forest and artificial neural network, were employed using tenfold cross-validation. After a randomization approach, the best predictive model showed Pearson's correlation coefficient ranges from 0.83 to 0.98 on training/testing (T<sup>274</sup>) dataset. The robustness of the developed models was cross-evaluated using William’s plot. The highly robust computational models are integrated into the web server. The ‘anti-Ebola’ web server is freely available at <ext-link ext-link-type="uri" xlink:href="https://bioinfo.imtech.res.in/manojk/antiebola">https://bioinfo.imtech.res.in/manojk/antiebola</ext-link>. We anticipate this will serve the scientific community for developing effective inhibitors against the Ebola virus.</p>
      <sec>
        <title>Graphic abstract</title>
        <p id="Par2">
          <graphic position="anchor" xlink:href="11030_2021_10291_Figa_HTML" id="MO1"/>
        </p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1007/s11030-021-10291-7.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Ebola virus</kwd>
      <kwd>Machine learning</kwd>
      <kwd>Prediction algorithm</kwd>
      <kwd>Random forest</kwd>
      <kwd>QSAR</kwd>
      <kwd>Web server</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001412</institution-id>
            <institution>Council of Scientific and Industrial Research, India</institution>
          </institution-wrap>
        </funding-source>
        <award-id>OLP0501</award-id>
        <award-id>OLP0143</award-id>
        <award-id>STS0038</award-id>
        <principal-award-recipient>
          <name>
            <surname>Kumar</surname>
            <given-names>Manoj</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© Springer Nature Switzerland AG 2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p id="Par3">Ebola virus (EBOV) is a member of <italic>Filoviridae</italic> family also known as Zaire ebolavirus, on the basis of the origin country, i.e., Democratic Republic of Congo (formerly Zaire). EBOV is responsible for thousands of deaths due to its periodic outbreaks since 1976. According to the World Health Organization (WHO), the fatality rate of the EBOV outbreak varies from 25 to 90% (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease">https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease</ext-link>). EBOV cases are mainly found in the region of sub-Saharan Africa and pass-through animals like a bat, other nonhuman primates or any patient infected with EBOV. As per WHO, the EBOV outbreak is classified under level 3 emergency due to its high mortality and fatality.</p>
    <p id="Par4">EBOV is a negative-stranded, enveloped, non-segmented and helical single-stranded RNA with 19-kb nucleotides. It constitutes eight structural and one nonstructural proteins. The structural proteins include the nucleoprotein (NP), glycoprotein (GP), soluble glycoprotein (sGP), RNA-dependent RNA polymerase (L) and four virion proteins (VP24, VP30, VP35, VP40) [<xref ref-type="bibr" rid="CR1">1</xref>]. As EBOV is an RNA virus, thus the development of effective antivirals against EBOV is a very challenging task. Currently, Favipiravir, Remdesivir, ZMapp and INMAZEB are the four most commonly used anti-Ebola agents for the treatment of EBOV infection. Among them, Favipiravir and Remdesivir are the ‘experimental’ category drugs that inhibit the viral polymerases while the ZMapp is the mixture of the three monoclonal antibodies, which are directed against the surface glycoproteins [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. INMAZEB, also known as REGN-EB3, is a mixture of three monoclonal antibodies, namely atoltivimab, maftivimab and odesivimab. It is the first USFDA-approved therapeutics in 2020 against EBOV infection. The Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) and Remdesivir (GS-5734) are in use as the broad-spectrum antiviral drugs. Initially, the Favipiravir was used to treat influenza virus, but now has been used against EBOV [<xref ref-type="bibr" rid="CR4">4</xref>]. Likewise, anti-Ebola drug Remdesivir was also repurposed to inhibit murine hepatic virus (MHV), Middle East respiratory syndrome (MERS-CoV), severe acute respiratory syndrome (SARS-CoV) and Nipah virus (NiV) [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
    <p id="Par5">Numerous computational studies are reported in the literature to highlight the use of machine learning in drug development against various pathogens. Todeschini R et al. described the importance of molecular descriptors in the process of designing the efficient drugs [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Hansch C et al. explained the importance of physicochemical parameters in the quantitative structure–activity relationship (QSAR) analysis [<xref ref-type="bibr" rid="CR8">8</xref>]. Matta CF explored the role of biophysical and biological properties in the formulation of QSAR models [<xref ref-type="bibr" rid="CR9">9</xref>]. Toussi CA et al. design the Ser/Thr-protein kinase inhibitors by using machine-trained elastic networks [<xref ref-type="bibr" rid="CR10">10</xref>]. However, our group previously implemented the machine learning approaches to develop computational methods to predict the antiviral compounds against various viruses like flaviviruses, Nipah virus and coronaviruses as AVCpred [<xref ref-type="bibr" rid="CR11">11</xref>], anti-Flavi [<xref ref-type="bibr" rid="CR12">12</xref>] and anti-Nipah [<xref ref-type="bibr" rid="CR13">13</xref>] and anti-corona [<xref ref-type="bibr" rid="CR14">14</xref>], respectively. Recently, we have developed a comprehensive repository of experimentally validated repurposed drugs against 23 viruses (including Ebola virus) responsible for causing epidemics/pandemics [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
    <p id="Par6">Furthermore, various computational approaches have been tried to identify repurposed or novel leads against EBOV. Anantpadma M et al. developed Bayesian machine learning models and identified three active molecules, namely tilorone, pyronaridine and quinacrine against EBOV [<xref ref-type="bibr" rid="CR16">16</xref>]. Kwofie SK et al. used pharmacoinformatics and molecular docking approach to prioritize 19 compounds against EBOV after screening 7675 natural products [<xref ref-type="bibr" rid="CR17">17</xref>]. Zhao Z et al. used a molecular dynamics approach to screen all FDA-approved drugs and finalized 15 potent drug candidates against EBOV [<xref ref-type="bibr" rid="CR18">18</xref>]. Ekins et al<italic>.</italic> integrated Bayesian machine learning models to filter out potential lead compounds against EBOV [<xref ref-type="bibr" rid="CR19">19</xref>]. However, most of the drug repurposing approach was done by various <italic>in vitro</italic> and <italic>in vivo</italic> assays, e.g., minigenome assay [<xref ref-type="bibr" rid="CR20">20</xref>], GIP/HIV core pseudovirus with firefly luciferase reporter gene [<xref ref-type="bibr" rid="CR21">21</xref>], HIV pseudovirions with high-throughput assay [<xref ref-type="bibr" rid="CR22">22</xref>] and many more. However, any dedicated web server to identify the promising drug candidates is not available in the literature. In the current study, we have developed a machine-learning-based pipeline named 'anti-Ebola' for the identification of inhibitors against Ebola virus.</p>
  </sec>
  <sec id="Sec2">
    <title>Methods</title>
    <sec id="Sec3">
      <title>Data collection</title>
      <p id="Par7">The anti-Ebola predictor was developed using the data of EBOV inhibitors available from our recently published ‘DrugRepV’ database [<xref ref-type="bibr" rid="CR15">15</xref>]. There are 868 compounds reported in this database, which were experimentally validated for anti-Ebola activities. However, we have selected only those molecules whose antiviral activities are given in terms of IC<sub>50</sub>/EC<sub>50</sub> so as to develop regression-based models. Further, we used strict quality control filters like IC<sub>50</sub>/EC<sub>50</sub> uniqueness, SMILES, assays, etc., to finalize our dataset. Finally, we obtained 305 unique inhibitors with the respective half-maximal inhibitory concentration (IC<sub>50</sub>/EC<sub>50</sub>) values from our database [<xref ref-type="bibr" rid="CR15">15</xref>]. The IC<sub>50</sub>/EC<sub>50</sub> values were converted into the negative logarithm of half-maximal inhibitory concentration (pIC<sub>50</sub>) using formula:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ pIC_{50} = - \log_{10} \left( {IC_{50} \left( M \right)} \right) $$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi>p</mml:mi><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mn>50</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mo>log</mml:mo><mml:mn>10</mml:mn></mml:msub><mml:mfenced close=")" open="("><mml:mrow><mml:mi>I</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mn>50</mml:mn></mml:msub><mml:mfenced close=")" open="("><mml:mi>M</mml:mi></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="11030_2021_10291_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where IC<sub>50</sub> is in the form of dimensionless activity that can be approximated numerically as molar concentrations. The higher pIC<sub>50</sub> indicates exponentially greater potency. The pIC<sub>50</sub> is used for the designing of various regression-based prediction algorithms [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Overall methodology of the anti-Ebola is available in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Overall methodology used to develop anti-Ebola predictor</p></caption><graphic xlink:href="11030_2021_10291_Fig1_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec4">
      <title>Data preparation</title>
      <p id="Par8">The chemical name was used to extract the chemical information like simplified molecular-input line-entry system (SMILES), which was then converted to 3D-SDF using obabel software [<xref ref-type="bibr" rid="CR24">24</xref>]. Finally, the 3D-SDF is used to calculate the molecular descriptor and fingerprints.</p>
      <p id="Par9">For running the machine learning algorithm, the overall dataset (305) was divided into training/testing (T<sup>274</sup>) and independent validation (V<sup>31</sup>) datasets using randomization approaches in six sets [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p>
    </sec>
    <sec id="Sec5">
      <title>PaDEL descriptor</title>
      <p id="Par10">The 3D-SDF structures were used for the calculation of 1D, 2D and 3D molecular descriptors as well as fingerprints. The PaDEL software is used for calculation of all the 17,968 descriptors available in the software [<xref ref-type="bibr" rid="CR27">27</xref>]. Further, to take only relevant features and to rule out the possibility of overfitting of the model, we performed feature selection.</p>
    </sec>
    <sec id="Sec6">
      <title>Feature selection</title>
      <p id="Par11">Feature selection is an important step to extract the most relevant features, remove irrelevant features and help to achieve high accuracy of the developed models [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. The feature selection was done using the support vector regression (SVR) implemented using libsvm using a parameter to control the number of support vectors. Finally, we extracted the most relevant 50 features out of 17,968 descriptors (Supplementary Table S2).</p>
    </sec>
    <sec id="Sec7">
      <title>Ten fold cross-validation</title>
      <p id="Par12">The tenfold cross-validation was used to develop the predictive models. In the tenfold cross, training/testing (T<sup>274</sup>) was divided equally into ten sets. Initially, the nine datasets were combined for training and the remaining one set for testing to finally calculate the model performance. Likewise, all the sets get a chance to become the testing set; however, the average performance of all the testing sets represents the overall performance of the model. Further, the performance of the developed model was cross-evaluated using the independent dataset, which was not used during training and testing.</p>
    </sec>
    <sec id="Sec8">
      <title>Machine learning techniques</title>
      <p id="Par13">In the current study, we implemented the three types of MLTs, i.e., support vector machine, random forest and artificial neural network techniques to develop predictive models.</p>
      <p id="Par14">Support vector machine is a supervised machine learning method which is used for both regression and classification-based problems. SVM constructs a set of hyperplanes which can be used to detect the regression/classification task. It is very effective for high-dimensional spaces [<xref ref-type="bibr" rid="CR30">30</xref>]. Different kernel functions can be used as a decision function. The main objective of the SVM is to find the hyperplane in N-dimensional (N is the number of features) space which identifies the data points. Random forest is an ensemble machine learning technique and has been extensively used for both classification and regression problems. It functions by making decision trees from the training dataset, and the output would be in the form of mean prediction [<xref ref-type="bibr" rid="CR31">31</xref>]. Artificial neural network is the organization of the connected units/nodes generally known as artificial neurons, which is analogous to the neurons in the human brain. The neural networks consist of input layer, output layer and hidden layers, which are used to transform the input to the reasonable output [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
    </sec>
    <sec id="Sec9">
      <title>Performance measure</title>
      <p id="Par15">The performance of the developed model was analyzed through Pearson’s correlation coefficient (PCC), mean absolute error (MAE) and root mean absolute error (RMSE).<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$PCC=\frac{n{\sum }_{n=1}^{n}{E}_{i}^{act }{E}_{i}^{pred }- {\sum }_{n=1}^{n}{E}_{i}^{act } {\sum }_{n=1}^{n}{E}_{i}^{pred } }{\sqrt{n{\sum }_{n=1}^{n}{{({E}_{i}^{act})}^{2}-({{\sum }_{n=1}^{n}E}_{i}^{act})}^{2}}- \sqrt{n{\sum }_{n=1}^{n}{{({E}_{i}^{pred})}^{2}-({{\sum }_{n=1}^{n}E}_{i}^{pred})}^{2}}}$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mi>P</mml:mi><mml:mi>C</mml:mi><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>n</mml:mi><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">act</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">pred</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">act</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">pred</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mi>n</mml:mi><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msup><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">act</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>-</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">act</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt><mml:mo>-</mml:mo><mml:msqrt><mml:mrow><mml:mi>n</mml:mi><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msup><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">pred</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>-</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">pred</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="11030_2021_10291_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$MAE = \frac{1}{n}\sum_{n=1}^{n}\left|{E}_{i}^{pred}-{E}_{i}^{act}\right|$$\end{document}</tex-math><mml:math id="M6" display="block"><mml:mrow><mml:mi>M</mml:mi><mml:mi>A</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mfenced close="|" open="|"><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">pred</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">act</mml:mi></mml:mrow></mml:msubsup></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="11030_2021_10291_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$RMSE = \sqrt{\frac{1}{n} \sum_{n=1}^{n}{({E}_{i}^{pred}- {E}_{i}^{act} )}^{2}}$$\end{document}</tex-math><mml:math id="M8" display="block"><mml:mrow><mml:mi>R</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">pred</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">act</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt></mml:mrow></mml:math><graphic xlink:href="11030_2021_10291_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par16">In eqns (<xref rid="Equ2" ref-type="">2</xref>), (<xref rid="Equ3" ref-type="">3</xref>) and (<xref rid="Equ4" ref-type="">4</xref>), <italic>n,</italic>
<inline-formula id="IEq1"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{i}^{pred}$$\end{document}</tex-math><mml:math id="M10"><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">pred</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="11030_2021_10291_Article_IEq1.gif"/></alternatives></inline-formula> and <inline-formula id="IEq2"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{i}^{act}$$\end{document}</tex-math><mml:math id="M12"><mml:msubsup><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">act</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="11030_2021_10291_Article_IEq2.gif"/></alternatives></inline-formula> are the size of the test set, predicted and actual efficiencies of Ebola inhibition, respectively.</p>
    </sec>
    <sec id="Sec10">
      <title>Applicability domain</title>
      <p id="Par17">The robustness of the developed model was evaluated using William’s plot. William’s plot depicts the relationship between standardized residuals and leverage. The leverage (h) is set as a warning threshold (h*) of 3*p/n; in it the p is 1 + the number of finally used descriptors and n is the size of the training dataset. However, the standardized residuals threshold was ± 3σ [<xref ref-type="bibr" rid="CR33">33</xref>]. The predictive model was robust if most data points lie within the warning threshold [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
    </sec>
    <sec id="Sec11">
      <title>Chemical analysis</title>
      <p id="Par18">We performed the analysis of the anti-Ebola compounds to check their chemical diversity. The diversity was checked by the multidimensional scaling (MDS) with a similarity score of 0.4. The cluster map was constructed through ChemmineR software [<xref ref-type="bibr" rid="CR34">34</xref>]. Further, the chemical dendrogram was formed using the Scaffoldhunter software through the chemical Fingerprints [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
    </sec>
    <sec id="Sec12">
      <title>Web server</title>
      <p id="Par19">The best performing predictive models are implemented in the form of web server 'anti-Ebola.' The front end of the web server is designed using HTML, CSS and PHP while the backend of the web server is constructed using python, perl and javascript.</p>
    </sec>
  </sec>
  <sec id="Sec13">
    <title>Results</title>
    <sec id="Sec14">
      <title>Performance of QSAR models</title>
      <p id="Par20">Among the six randomized training/testing (T<sup>274</sup>) datasets, the best QSAR model displayed a PCC of 0.83, 0.98 and 0.95 for SVM, RF and ANN machine learning techniques, respectively, on the best performing dataset (Table <xref rid="Tab1" ref-type="table">1</xref>). Cross-validation of the training/testing dataset was done using independent validation (V<sup>31</sup>) dataset and showed the PCC values of 0.65, 0.62 and 0.64 for SVM, RF and ANN correspondingly (Table <xref rid="Tab1" ref-type="table">1</xref>). The performance of all the remaining five training/testing and independent validation datasets is provided in Supplementary Table S1.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Table depicting the performance of training/testing (T274) and independent validation data set (V31) for the support vector machine, random forest and artificial neural network</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Ebola</th><th align="left" colspan="3">Training/Testing dataset</th><th align="left" colspan="3">Independent Validation dataset</th></tr><tr><th align="left">Algorithm</th><th align="left">Dataset</th><th align="left">MAE</th><th align="left">RMSE</th><th align="left">PCC</th><th align="left">MAE</th><th align="left">RMSE</th><th align="left">PCC</th></tr></thead><tbody><tr><td align="left">SVM</td><td align="left">T<sup>274</sup> + V<sup>31</sup></td><td align="left">0.33</td><td align="left">0.47</td><td align="left">0.83</td><td align="left">0.48</td><td align="left">0.66</td><td align="left">0.65</td></tr><tr><td align="left">RF</td><td align="left">T<sup>274</sup> + V<sup>31</sup></td><td align="left">0.19</td><td align="left">0.28</td><td align="left">0.98</td><td align="left">0.52</td><td align="left">0.63</td><td align="left">0.62</td></tr><tr><td align="left">ANN</td><td align="left">T<sup>274</sup> + V<sup>31</sup></td><td align="left">0.23</td><td align="left">0.29</td><td align="left">0.95</td><td align="left">0.76</td><td align="left">0.97</td><td align="left">0.64</td></tr></tbody></table><table-wrap-foot><p>*MAE, mean absolute error; RMSE, root mean absolute error; PCC, Pearson’s correlation coefficient; SVM, support vector machine; RF, random forest; ANN, artificial neural network</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec15">
      <title>Applicability domain</title>
      <p id="Par21">While plotting William’s plot, we found that most of the data points of both training/testing and validation data lie within the warning threshold, showing that the developed model is robust. We found the h* is 1.21, 1.25 and 1.18, while the 3σ is 2.0, 1.9, 1.0, respectively, for SVM (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a), RF (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b) and ANN (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). Both the h* and the 3σ were plotted as a warning threshold in William’s plot. William's plot shows the relationship between standardized residuals and leverage (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Applicability domain of the anti-Ebola compounds presented by William’s plot. <bold>a</bold> random forest, <bold>b</bold> support vector machine, <bold>c</bold> artificial neural Network</p></caption><graphic xlink:href="11030_2021_10291_Fig2_HTML" id="MO3"/></fig></p>
    </sec>
    <sec id="Sec16">
      <title>Chemical analysis</title>
      <p id="Par22">We performed an analysis of the anti-Ebola chemicals to explore the chemical variability. For the same, we used the multidimensional scaling (MDS) whose distance matrix was calculated by ‘<italic>all-against-all’</italic> comparison of compounds through atom pair similarity measures (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a). Further, the generated similarity scores were transferred into the distance values through the cmdscale method. The cluster map shows the diversity up to 320 clusters with the similarity cutoff of 0.4. Further, the chemical dendrogram was also constructed to check the details of the chemical scaffolds using the EstateNumericalFingerprint (largest fragment, deglycosilated) physicochemical properties. It showed that the highest number of the molecules, i.e., 55, comes under the parent chemical with benzene ring (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b). Furthermore, 32 molecules consisted of pyridine parent molecules. Remaining information of all the anti-Ebola molecules is provided in Fig. <xref rid="Fig3" ref-type="fig">3</xref>b.<fig id="Fig3"><label>Fig. 3</label><caption><p>Chemical analysis of anti-Ebola compounds. <bold>a</bold> Scatter plot showing the diversity of the 305 anti-Ebola compounds, <bold>b</bold> chemical dendrogram of the anti-Ebola compounds showing the chemical side chain similarity among them</p></caption><graphic xlink:href="11030_2021_10291_Fig3_HTML" id="MO4"/></fig></p>
    </sec>
    <sec id="Sec17">
      <title>Web server</title>
      <p id="Par23">The web server 'anti-Ebola' is freely available at: <ext-link ext-link-type="uri" xlink:href="https://bioinfo.imtech.res.in/manojk/antiebola">https://bioinfo.imtech.res.in/manojk/antiebola</ext-link>. It contains the predictor, where the input query can be provided in the form of a SDF and the output displayed as a tabular form with information of SMILES, predicted IC<sub>50</sub> in μM along with its structure. To make our web server more informative, we have also provided the important drug-like properties of the input query. We used filter-it software to calculate these drug-likeness properties. It includes the drug-likeness properties, namely Lipinski acceptor, Lipinski donor, H-bond acceptors, H-bond donor, molecular weight, logP, rotatable and rigid bonds, formal charges and molecular formula. The H-bond acceptor shows the number of hydrogen bond acceptors; it includes an aromatic N with no connected H atoms, no amide nitrogen and which doesn’t possess any positive charge; an aliphatic N with no connected H atoms as well as no positive charge on it; any O atom without any positive charge; and a thionyl sulfur atom. The H-bond donor shows the number of hydrogen bond donors and includes any H bonded to a N; any H bonded to an O; and any H bonded to a S. Lipinski acceptor refers to the Lipinski H-bond acceptor like any N or O atom which may or may not be connected to any H atom. Lipinski donor denotes the Lipinski H-bond donor e.g., each H-atom connected to N or O. Here, Lipinski’s rule of five is the rule of thumb to determine the drug likeness of a compound. It indicates whether the compound has certain biological, chemical, pharmacological activities appropriate for human consumption.</p>
    </sec>
    <sec id="Sec18">
      <title>Case study</title>
      <p id="Par24">We have checked the utility of our web server by predicting the IC<sub>50</sub>/EC<sub>50</sub> values of the already identified promising hits from other studies. We used an anti-Ebola SVM predictive model to predict anti-EBOV activity of these lead molecules. For example, Zheng et al<italic>.</italic> identified Indinavir, Maraviroc, Abacavir, etc. as good anti-EBOV compounds [<xref ref-type="bibr" rid="CR18">18</xref>]. Interestingly, our predictive model also predicts high inhibition efficacy of Indinavir (IC<sub>50</sub> 0.03uM), Maraviroc (IC<sub>50</sub> 0.30uM), Abacavir (IC<sub>50</sub> 1.27uM). Likewise, Anantpadma A et al. identified three effective anti-EBOV drugs, namely Tilorone, Pyronaridine and Quinacrine with K<sub>d</sub> values of 0.73 uM, 7.34uM and 7.55 uM [<xref ref-type="bibr" rid="CR16">16</xref>]. These three lead molecules also show potential inhibition efficacy by our ‘anti-Ebola’ web server such as Tilorone (IC<sub>50</sub> 1.95uM), Pyronaridine (IC<sub>50</sub> 0.50uM) and Quinacrine (IC<sub>50</sub> 0.002uM). Thus, these findings further validate the utility of our prediction algorithm.</p>
    </sec>
  </sec>
  <sec id="Sec19">
    <title>Discussion</title>
    <p id="Par25">Ebola is a dreadful pathogen, which is responsible for causing epidemics in the past, with a high mortality rate [<xref ref-type="bibr" rid="CR36">36</xref>]. There is a need for developing effective anti-Ebola agents. In this endeavor, intervention of the computational approaches would accelerate the research in the field [<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, in the current study, we provided machine learning-based prediction models to identify novel and effective anti-Ebola compounds. Apart from that, we also analyzed the chemical diversity of the available Ebola inhibitors.</p>
    <p id="Par26">We implement three MLTs like SVM, RF and ANN to develop effective predictive models. SVM, RF and ANN are the machine learning techniques that work on different principles. For example, the SVM is a nonlinear algorithm, RF works with a decision tree group of algorithms, and the ANN is a neural networks-based algorithm. Various researchers have used these techniques in numerous studies [<xref ref-type="bibr" rid="CR37">37</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]. Likewise, we had also used these techniques to develop predictive algorithms like QSPpred [<xref ref-type="bibr" rid="CR25">25</xref>], VIRsiRNApred [<xref ref-type="bibr" rid="CR41">41</xref>], AVP-IC50Pred [<xref ref-type="bibr" rid="CR42">42</xref>], anti-flavi [<xref ref-type="bibr" rid="CR12">12</xref>] and many more. For the development of the high-quality predictive models, we extracted the highly relevant features out of the 17,968 (1D, 2D, 3D and fingerprints) features from the available anti-Ebola compounds. Among the three MLTs, the PCC of the SVM, RF and ANN ranges from 0.83 to 0.98. Further, we checked the robustness of the developed models by constructing William's plot (applicability domain). Further, we implemented the developed models in the form of a web server named ‘anti-Ebola’ (<ext-link ext-link-type="uri" xlink:href="https://bioinfo.imtech.res.in/manojk/antiebola/">https://bioinfo.imtech.res.in/manojk/antiebola/</ext-link>). The implementation of the predictive models in the form of a web server makes them easily accessible for the users. Apart from that, we analyzed the chemical diversity of the available EBOV inhibitors. We noticed that the available anti-Ebola molecules showed high chemical diversity. However, the highest (55) amount of the molecules are derivatives of the benzene parent compound, followed by the 32 molecules which are the derivative of the pyridine heterocyclic ring. This is an important approach based on the implementation of the MLTs on the available experimentally validated anti-Ebola molecules. Thus, our study would be very important for identification of the new and promising anti-Ebola agents. Researchers can use our web server to identify the promising repurposed drug candidates also.</p>
    <p id="Par27">Few researchers performed computational studies for the identification of repurposed drugs against EBOV. These computational studies include the use of Bayesian machine learning models, molecular simulations, molecular docking, etc. [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. These studies used different datasets as input like natural products, FDA-approved drugs and small active molecules from repositories. However, our study is different from these approaches, as we have incorporated three different MLTs for the prediction of anti-EBOV agents. For the development of the predictive models, we used the experimentally validated anti-EBOV compounds which are chemically diverse. Furthermore, our predictive models are incorporated as a web server which is not available with any of the previously published computational approaches for EBOV.</p>
    <p id="Par28">The frequent outbreaks of EBOV with high mortality and fatality rate are serious concerns worldwide. As EBOV is a dangerous infectious pathogen and comes under the Biosafety Level-4 (BSL-4) category, it requires a highly specialized laboratory to work. Therefore, designing an anti-Ebola agent is a challenging task. Thus, the intervention of computational approaches would be of great help in speeding up the identification of effective EBOV inhibitors. In this endeavor, we have developed the machine learning-based QSAR regression model 'anti-Ebola.' We will update the web server on a yearly basis or whenever a significant amount of data is available. Thus this 'anti-Ebola' web server would be helpful to researchers to predict Ebola inhibitors and the antiviral therapeutic development.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec20">
      <p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11030_2021_10291_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 17 kb)</p></caption></media></supplementary-material></p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This work was supported by the grants from the CSIR-Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR) (OLP0501, OLP0143 and STS0038).</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1" notes-type="COI-statement">
      <title>Conflict of interest</title>
      <p id="Par29">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Beniac</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Booth</surname>
            <given-names>TF</given-names>
          </name>
        </person-group>
        <article-title>Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 Å resolution</article-title>
        <source>Sci Rep</source>
        <year>2017</year>
        <volume>7</volume>
        <fpage>46374</fpage>
        <pub-id pub-id-type="doi">10.1038/srep46374</pub-id>
        <?supplied-pmid 28397863?>
        <pub-id pub-id-type="pmid">28397863</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Adhikari</surname>
            <given-names>NKJ</given-names>
          </name>
          <name>
            <surname>Kwon</surname>
            <given-names>HY</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Anti-Ebola therapy for patients with Ebola virus disease: a systematic review</article-title>
        <source>BMC Infect Dis</source>
        <year>2019</year>
        <volume>19</volume>
        <fpage>376</fpage>
        <pub-id pub-id-type="doi">10.1186/s12879-019-3980-9</pub-id>
        <?supplied-pmid 31046707?>
        <pub-id pub-id-type="pmid">31046707</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Keller</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Richard Stiehm</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Passive Immunity in Prevention and Treatment of Infectious Diseases</article-title>
        <source>Clin Microbiol Rev</source>
        <year>2000</year>
        <volume>13</volume>
        <fpage>602</fpage>
        <lpage>614</lpage>
        <pub-id pub-id-type="doi">10.1128/cmr.13.4.602</pub-id>
        <?supplied-pmid 11023960?>
        <pub-id pub-id-type="pmid">11023960</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guedj</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Piorkowski</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Jacquot</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques</article-title>
        <source>PLoS Med</source>
        <year>2018</year>
        <volume>15</volume>
        <fpage>e1002535</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pmed.1002535</pub-id>
        <?supplied-pmid 29584730?>
        <pub-id pub-id-type="pmid">29584730</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <mixed-citation publication-type="other">Lo MK, Feldmann F, Gary JM, et al (2019) Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med 11:eaau9242. 10.1126/scitranslmed.aau9242</mixed-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <mixed-citation publication-type="other">Todeschini R, Consonni V (2009) Molecular Descriptors for Chemoinformatics: Volume I: Alphabetical Listing / Volume II: Appendices, References. John Wiley &amp; Sons</mixed-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <mixed-citation publication-type="other">Todeschini R, Consonni V (2009) Molecular Descriptors for Chemoinformatics, 2 Volume Set: Volume I: Alphabetical Listing / Volume II: Appendices, References. Wiley-VCH</mixed-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <mixed-citation publication-type="other">Hansch C, Leo A, Pomona College Albert Leo (1995) Exploring QSAR.: Fundamentals and applications in chemistry and biology. Amer Chemical Society</mixed-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Matta</surname>
            <given-names>CF</given-names>
          </name>
        </person-group>
        <article-title>Modeling biophysical and biological properties from the characteristics of the molecular electron density, electron localization and delocalization matrices and the electrostatic potential</article-title>
        <source>J Comput Chem</source>
        <year>2014</year>
        <volume>35</volume>
        <fpage>1165</fpage>
        <lpage>1198</lpage>
        <pub-id pub-id-type="doi">10.1002/jcc.23608</pub-id>
        <?supplied-pmid 24777743?>
        <pub-id pub-id-type="pmid">24777743</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Toussi</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Haddadnia</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Matta</surname>
            <given-names>CF</given-names>
          </name>
        </person-group>
        <article-title>Drug design by machine-trained elastic networks: predicting Ser/Thr-protein kinase inhibitors’ activities</article-title>
        <source>Mol Divers</source>
        <year>2021</year>
        <volume>25</volume>
        <fpage>899</fpage>
        <lpage>909</lpage>
        <pub-id pub-id-type="doi">10.1007/s11030-020-10074-6</pub-id>
        <?supplied-pmid 32222890?>
        <pub-id pub-id-type="pmid">32222890</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Qureshi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kaur</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>AVCpred: an integrated web server for prediction and design of antiviral compounds</article-title>
        <source>Chem Biol Drug Des</source>
        <year>2017</year>
        <volume>89</volume>
        <fpage>74</fpage>
        <lpage>83</lpage>
        <pub-id pub-id-type="doi">10.1111/cbdd.12834</pub-id>
        <?supplied-pmid 27490990?>
        <pub-id pub-id-type="pmid">27490990</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rajput</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Anti-flavi: A Web Platform to Predict Inhibitors of Flaviviruses Using QSAR and Peptidomimetic Approaches</article-title>
        <source>Front Microbiol</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>3121</fpage>
        <pub-id pub-id-type="doi">10.3389/fmicb.2018.03121</pub-id>
        <?supplied-pmid 30619195?>
        <pub-id pub-id-type="pmid">30619195</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rajput</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Computational Identification of Inhibitors Using QSAR Approach Against Nipah Virus</article-title>
        <source>Front Pharmacol</source>
        <year>2019</year>
        <volume>10</volume>
        <fpage>71</fpage>
        <pub-id pub-id-type="doi">10.3389/fphar.2019.00071</pub-id>
        <?supplied-pmid 30809147?>
        <pub-id pub-id-type="pmid">30809147</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rajput</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Thakur</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mukhopadhyay</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning</article-title>
        <source>Comput Struct Biotechnol J</source>
        <year>2021</year>
        <volume>19</volume>
        <fpage>3133</fpage>
        <lpage>3148</lpage>
        <pub-id pub-id-type="doi">10.1016/j.csbj.2021.05.037</pub-id>
        <?supplied-pmid 34055238?>
        <pub-id pub-id-type="pmid">34055238</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rajput</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Megha</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses</article-title>
        <source>Brief Bioinform</source>
        <year>2021</year>
        <volume>22</volume>
        <fpage>1076</fpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbaa421</pub-id>
        <?supplied-pmid 33480398?>
        <pub-id pub-id-type="pmid">33480398</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Anantpadma</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lane</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Zorn</surname>
            <given-names>KM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads</article-title>
        <source>ACS Omega</source>
        <year>2019</year>
        <volume>4</volume>
        <fpage>2353</fpage>
        <lpage>2361</lpage>
        <pub-id pub-id-type="doi">10.1021/acsomega.8b02948</pub-id>
        <?supplied-pmid 30729228?>
        <pub-id pub-id-type="pmid">30729228</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kwofie</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Broni</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Teye</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24</article-title>
        <source>Comput Biol Med</source>
        <year>2019</year>
        <volume>113</volume>
        <fpage>103414</fpage>
        <pub-id pub-id-type="doi">10.1016/j.compbiomed.2019.103414</pub-id>
        <?supplied-pmid 31536833?>
        <pub-id pub-id-type="pmid">31536833</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology</article-title>
        <source>BMC Bioinformatics</source>
        <year>2016</year>
        <volume>17</volume>
        <fpage>90</fpage>
        <pub-id pub-id-type="doi">10.1186/s12859-016-0941-9</pub-id>
        <?supplied-pmid 26887654?>
        <pub-id pub-id-type="pmid">26887654</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <mixed-citation publication-type="other">Ekins S, Freundlich JS, Clark AM, et al (2015) Machine learning models identify molecules active against the Ebola virus. F1000Res 4:1091. 10.12688/f1000research.7217.3</mixed-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Edwards</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Pietzsch</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vausselin</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication</article-title>
        <source>ACS Infect Dis</source>
        <year>2015</year>
        <volume>1</volume>
        <fpage>380</fpage>
        <lpage>387</lpage>
        <pub-id pub-id-type="doi">10.1021/acsinfecdis.5b00053</pub-id>
        <?supplied-pmid 26284260?>
        <pub-id pub-id-type="pmid">26284260</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Teicoplanin inhibits Ebola pseudovirus infection in cell culture</article-title>
        <source>Antiviral Res</source>
        <year>2016</year>
        <volume>125</volume>
        <fpage>1</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.11.003</pub-id>
        <?supplied-pmid 26585243?>
        <pub-id pub-id-type="pmid">26585243</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Lear-Rooney</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Johansen</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists</article-title>
        <source>J Virol</source>
        <year>2015</year>
        <volume>89</volume>
        <fpage>9932</fpage>
        <lpage>9938</lpage>
        <pub-id pub-id-type="doi">10.1128/JVI.01337-15</pub-id>
        <?supplied-pmid 26202243?>
        <pub-id pub-id-type="pmid">26202243</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kalliokoski</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kramer</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vulpetti</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gedeck</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Comparability of Mixed IC50 Data – A Statistical Analysis</article-title>
        <source>PLoS ONE</source>
        <year>2013</year>
        <volume>8</volume>
        <fpage>e61007</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0061007</pub-id>
        <?supplied-pmid 23613770?>
        <pub-id pub-id-type="pmid">23613770</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>O’Boyle</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Banck</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>CA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Open Babel: An open chemical toolbox</article-title>
        <source>J Cheminform</source>
        <year>2011</year>
        <volume>3</volume>
        <fpage>33</fpage>
        <pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>
        <?supplied-pmid 21982300?>
        <pub-id pub-id-type="pmid">21982300</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rajput</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gupta</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Prediction and analysis of quorum sensing peptides based on sequence features</article-title>
        <source>PLoS ONE</source>
        <year>2015</year>
        <volume>10</volume>
        <fpage>e0120066</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0120066</pub-id>
        <?supplied-pmid 25781990?>
        <pub-id pub-id-type="pmid">25781990</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Thakur</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rajput</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>MSLVP: prediction of multiple subcellular localization of viral proteins using a support vector machine</article-title>
        <source>Mol Biosyst</source>
        <year>2016</year>
        <volume>12</volume>
        <fpage>2572</fpage>
        <lpage>2586</lpage>
        <pub-id pub-id-type="doi">10.1039/c6mb00241b</pub-id>
        <?supplied-pmid 27272007?>
        <pub-id pub-id-type="pmid">27272007</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yap</surname>
            <given-names>CW</given-names>
          </name>
        </person-group>
        <article-title>PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints</article-title>
        <source>J Comput Chem</source>
        <year>2011</year>
        <volume>32</volume>
        <fpage>1466</fpage>
        <lpage>1474</lpage>
        <pub-id pub-id-type="doi">10.1002/jcc.21707</pub-id>
        <?supplied-pmid 21425294?>
        <pub-id pub-id-type="pmid">21425294</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hira</surname>
            <given-names>ZM</given-names>
          </name>
          <name>
            <surname>Gillies</surname>
            <given-names>DF</given-names>
          </name>
        </person-group>
        <article-title>A Review of Feature Selection and Feature Extraction Methods Applied on Microarray Data</article-title>
        <source>Adv Bioinformatics</source>
        <year>2015</year>
        <volume>2015</volume>
        <fpage>198363</fpage>
        <pub-id pub-id-type="doi">10.1155/2015/198363</pub-id>
        <?supplied-pmid 26170834?>
        <pub-id pub-id-type="pmid">26170834</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rajput</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Thakur</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sharma</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>aBiofilm: a resource of anti-biofilm agents and their potential implications in targeting antibiotic drug resistance</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D894</fpage>
        <lpage>D900</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1157</pub-id>
        <?supplied-pmid 29156005?>
        <pub-id pub-id-type="pmid">29156005</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cortes</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vapnik</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <source>Mach Learn</source>
        <year>1995</year>
        <volume>20</volume>
        <fpage>273</fpage>
        <lpage>297</lpage>
        <pub-id pub-id-type="doi">10.1023/a:1022627411411</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Petkovic</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Altman</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Vigil</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Improving the explainability of Random Forest classifier - user centered approach</article-title>
        <source>Pac Symp Biocomput</source>
        <year>2018</year>
        <volume>23</volume>
        <fpage>204</fpage>
        <lpage>215</lpage>
        <pub-id pub-id-type="doi">10.1142/9789813235533_0019</pub-id>
        <?supplied-pmid 29218882?>
        <pub-id pub-id-type="pmid">29218882</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jain</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Mao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Mohiuddin</surname>
            <given-names>KM</given-names>
          </name>
        </person-group>
        <article-title>Artificial neural networks: a tutorial</article-title>
        <source>Computer</source>
        <year>1996</year>
        <volume>29</volume>
        <fpage>31</fpage>
        <lpage>44</lpage>
        <pub-id pub-id-type="doi">10.1109/2.485891</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fechner</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Jahn</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hinselmann</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Zell</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Estimation of the applicability domain of kernel-based machine learning models for virtual screening</article-title>
        <source>J Cheminform</source>
        <year>2010</year>
        <volume>2</volume>
        <fpage>2</fpage>
        <pub-id pub-id-type="doi">10.1186/1758-2946-2-2</pub-id>
        <?supplied-pmid 20222949?>
        <pub-id pub-id-type="pmid">20222949</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Charisi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>L-C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>ChemmineR: a compound mining framework for R</article-title>
        <source>Bioinformatics</source>
        <year>2008</year>
        <volume>24</volume>
        <fpage>1733</fpage>
        <lpage>1734</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btn307</pub-id>
        <?supplied-pmid 18596077?>
        <pub-id pub-id-type="pmid">18596077</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schäfer</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kriege</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Humbeck</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Scaffold Hunter: a comprehensive visual analytics framework for drug discovery</article-title>
        <source>J Cheminform</source>
        <year>2017</year>
        <volume>9</volume>
        <fpage>28</fpage>
        <pub-id pub-id-type="doi">10.1186/s13321-017-0213-3</pub-id>
        <?supplied-pmid 29086162?>
        <pub-id pub-id-type="pmid">29086162</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Lahai</surname>
            <given-names>JI</given-names>
          </name>
        </person-group>
        <source>The Ebola Pandemic in Sierra Leone</source>
        <year>2017</year>
        <publisher-loc>Cham</publisher-loc>
        <publisher-name>Palgrave Macmillan</publisher-name>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jovic</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bogunovic</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Electrocardiogram analysis using a combination of statistical, geometric and nonlinear heart rate variability features</article-title>
        <source>Artif Intell Med</source>
        <year>2011</year>
        <volume>51</volume>
        <fpage>175</fpage>
        <lpage>186</lpage>
        <pub-id pub-id-type="doi">10.1016/j.artmed.2010.09.005</pub-id>
        <?supplied-pmid 20980134?>
        <pub-id pub-id-type="pmid">20980134</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>You</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Comparison of ANN (MLP), ANFIS, SVM and RF models for the online classification of heating value of burning municipal solid waste in circulating fluidized bed incinerators</article-title>
        <source>Waste Manag</source>
        <year>2017</year>
        <volume>68</volume>
        <fpage>186</fpage>
        <lpage>197</lpage>
        <pub-id pub-id-type="doi">10.1016/j.wasman.2017.03.044</pub-id>
        <?supplied-pmid 28408281?>
        <pub-id pub-id-type="pmid">28408281</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Development and head-to-head comparison of machine-learning models to identify patients requiring prostate biopsy</article-title>
        <source>BMC Urol</source>
        <year>2021</year>
        <volume>21</volume>
        <fpage>80</fpage>
        <pub-id pub-id-type="doi">10.1186/s12894-021-00849-w</pub-id>
        <?supplied-pmid 33993876?>
        <pub-id pub-id-type="pmid">33993876</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mirsadeghi</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Haji Hosseini</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Banaei-Moghaddam</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Kavousi</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer</article-title>
        <source>BMC Med Genomics</source>
        <year>2021</year>
        <volume>14</volume>
        <fpage>122</fpage>
        <pub-id pub-id-type="doi">10.1186/s12920-021-00974-3</pub-id>
        <?supplied-pmid 33962648?>
        <pub-id pub-id-type="pmid">33962648</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Qureshi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Thakur</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses</article-title>
        <source>J Transl Med</source>
        <year>2013</year>
        <volume>11</volume>
        <fpage>305</fpage>
        <pub-id pub-id-type="doi">10.1186/1479-5876-11-305</pub-id>
        <?supplied-pmid 24330765?>
        <pub-id pub-id-type="pmid">24330765</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Qureshi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tandon</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>AVP-IC50 Pred: Multiple machine learning techniques-based prediction of peptide antiviral activity in terms of half maximal inhibitory concentration (IC50)</article-title>
        <source>Biopolymers</source>
        <year>2015</year>
        <volume>104</volume>
        <fpage>753</fpage>
        <lpage>763</lpage>
        <pub-id pub-id-type="doi">10.1002/bip.22703</pub-id>
        <?supplied-pmid 26213387?>
        <pub-id pub-id-type="pmid">26213387</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
